Here, we extend the number of longitudinal plasma samples from our initial ALK+ NSCLC cohort and for the first time, using tNGS and sWGS data, identify threshold values for changes in variant allele frequencies (VAFs) and t-MAD scores that potentially indicate disease progression earlier than current conventional modalities. The gene discussed is ALK; the disease is non-small cell lung carcinoma.